Technology | May 08, 2015

Pie Medical Imaging Upgrades 3mensio Structural Heart Planning Platform

New workflows enable advanced visualization for mitral valve replacement, other structural heart interventions

Pie Medical Imaging, 3mensio Structural Heart, mitral, septal crossing, workflow

May 8, 2015 — Pie Medical Imaging announces its new release of 3mensio Structural Heart, dedicated to planning of structural heart interventions. This new release contains an optimized Mitral workflow and a new Septal Crossing workflow for planning of mitral valve procedures to determine the appropriate access route based on computed tomography (CT) images. These new innovations will be shown at the EuroPCR in Paris, May 19- 22.

More insight on the size and shape of the mitral valve is vital for pre-procedural planning of mitral valve replacement and repair procedures. The Mitral workflow provides advanced visualization and sizing of the mitral annulus and its surrounding structures like the aortic valve and coronary arteries. Also the possible impact on the left ventricular outflow tract (LVOT) clearance of placing a valve can be simulated.
 
The Septal Crossing workflow enables visualization of cardiac structures in a simulated angioview. In this simulated angioview, anatomic relations between the interatrial septum, left atrial appendage (LAA) ostium, mitral annulus and vena cava can be easily determined.

For more information: www.piemedicalimaging.com

Related Content

National Survey Of Heart Valve Patients Shows Importance Of Seeking Treatment Early
News | Heart Valve Technology | August 12, 2020
August 12, 2020 — A national survey conducted by the patient advocacy group...
CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.

News | Heart Valve Technology | August 05, 2020
August 5, 2020 – Minneapolis-based CardioMech AS, a medical device company developing a transfemoral, transseptally d
The Edwards Konect Resilia aortic valved conduit (AVC).
News | Heart Valve Technology | July 15, 2020
July 15, 2020 —  The U.S. Food and Drug Administration (FDA) granted clearance for the Edwards Lifesciences Corp.
The Foldax Tria surgical valve reimagines the heart valve by incorporating a new, proprietary biopolymer, what the vendor calls LifePolymer, with an innovative valve design intended to eliminate calcification, withstand stresses and strains without failure, and restore patient quality of life without lifelong use of anticoagulants. Tria is also the first heart valve to be robotically manufactured, reducing variability, enabling high precision, repeatability and better quality control.
News | Heart Valve Technology | June 23, 2020
June 23, 2020 – Heart valve start-up Foldax is looking to reinventi
SMT Enters Structural Heart Market With Acquisition of Vascular Concepts. The company's Hydra TAVR (TAVI) valve gained European CE mark clearance in June 2020.
News | Heart Valve Technology | June 19, 2020
June 19, 2020 — SMT (Sahajanand Medical Technologies Pvt.
SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company of India focused on cardiology, announced it Hydra transcatheter aortic valve replacement (TAVR) device received European CE mark approval. It is indicated for the treatment of patients diagnosed with aortic stenosis. #SMT #HYDRA #TAVR

The self-expanding SMT Hydra transcatheter aortic valve replacement (TAVR) device.

Feature | Heart Valve Technology | June 09, 2020
June 9, 2020 — SMT (Sahajanand Medical Technology Private Ltd.), a leading medical device company in India focused on
News | Heart Valve Technology | June 08, 2020
June 8, 2020 — Edwards Lifesciences Corp.
Edwards Lifesciences Pascal Tricuspid Valve Transcatheter Repair System Approved in Europe
News | Heart Valve Technology | May 18, 2020
May 18, 2020 — The Edwards Lifesciences Corp.